An often overlooked risk for patients receiving dialysis for kidney failure or related conditions is infection. Unfortunately, infections among dialysis patients are both common and serious, presenting a significant complication and an unmet medical need. CorMedix Inc. (NASDAQ: CRMD), a clinical-stage biopharmaceutical company, is working to develop catheter lock products to prevent certain types of dialysis-related bloodstream infections and may be poised to fill this gap.
The company's catheter lock solution (CLS) DefenCath provides antimicrobial protection for central venous catheter users. Interim results that the company announced in mid-December 2025 are highly promising and support a broadly bullish outlook. Investors looking for a commercial execution story with a clear clinical proof point should keep an eye on CorMedix into early 2026.
